<div class="table-wrap table anchored whole_rhythm" id="T1">
<h3>Table 1</h3>
<!--caption a7--><div class="caption"><p id="__p16">Baseline demographics, disease characteristics and prior therapies of the pooled predictors analysis populations</p></div>
<div data-largeobj="" data-largeobj-link-rid="largeobj_idm140576998550624" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table">
<thead>
<tr>
<td rowspan="2" colspan="1" valign="bottom" align="left">Characteristic</td>
<td colspan="2" rowspan="1" valign="bottom" align="left">Pooled for prediction of insufficient response to methotrexate (n=687)</td>
<td colspan="2" rowspan="1" valign="bottom" align="left">Pooled for prediction of CRRP (n=670)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="bottom" align="left">Insufficient responders (n=525)</td>
<td rowspan="1" colspan="1" valign="bottom" align="left">Responders (n=162)</td>
<td rowspan="1" colspan="1" valign="bottom" align="left">CRRP (n=171)</td>
<td rowspan="1" colspan="1" valign="bottom" align="left">No CRRP (n=499)</td>
</tr>
</thead>
<tbody>
<tr><td colspan="5" rowspan="1" valign="top" align="left">Demographic characteristics</td></tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> Women, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">398 (76)</td>
<td rowspan="1" colspan="1" valign="top" align="center">113 (70)</td>
<td rowspan="1" colspan="1" valign="top" align="center">126 (74)</td>
<td rowspan="1" colspan="1" valign="top" align="center">372 (75)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> White, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">483 (92)</td>
<td rowspan="1" colspan="1" valign="top" align="center">148 (91)</td>
<td rowspan="1" colspan="1" valign="top" align="center">158 (92)</td>
<td rowspan="1" colspan="1" valign="top" align="center">456 (91)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> Age (years)</td>
<td rowspan="1" colspan="1" valign="top" align="center">51.3 (13.7)</td>
<td rowspan="1" colspan="1" valign="top" align="center">48.8 (13.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">50.9 (14.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">50.7 (13.3)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> RA duration (years)</td>
<td rowspan="1" colspan="1" valign="top" align="center">0.5 (0.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">0.5 (0.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">0.5 (0.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">0.5 (0.6)</td>
</tr>
<tr><td colspan="5" rowspan="1" valign="top" align="left">Disease characteristics</td></tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> CRP (mg/L)</td>
<td rowspan="1" colspan="1" valign="top" align="center">35.7 (36.5)</td>
<td rowspan="1" colspan="1" valign="top" align="center">26.4 (28.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">50.7 (45.7)</td>
<td rowspan="1" colspan="1" valign="top" align="center">27.6 (28.1)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> TJC68</td>
<td rowspan="1" colspan="1" valign="top" align="center">30.1 (14.8)</td>
<td rowspan="1" colspan="1" valign="top" align="center">23.9 (12.7)</td>
<td rowspan="1" colspan="1" valign="top" align="center">30.7 (13.7)</td>
<td rowspan="1" colspan="1" valign="top" align="center">28.0 (14.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> SJC66</td>
<td rowspan="1" colspan="1" valign="top" align="center">20.4 (11.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">15.6 (9.1)</td>
<td rowspan="1" colspan="1" valign="top" align="center">22.3 (11.5)</td>
<td rowspan="1" colspan="1" valign="top" align="center">18.3 (10.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> DAS28(CRP)</td>
<td rowspan="1" colspan="1" valign="top" align="center">6.2 (0.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">5.6 (1.0)</td>
<td rowspan="1" colspan="1" valign="top" align="center">6.4 (0.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">6.0 (1.0)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> SDAI</td>
<td rowspan="1" colspan="1" valign="top" align="center">46.7 (13.8)</td>
<td rowspan="1" colspan="1" valign="top" align="center">38.0 (13.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">49.4 (14.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">43.1 (14.0)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> CDAI</td>
<td rowspan="1" colspan="1" valign="top" align="center">43.3 (12.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">35.4 (12.3)</td>
<td rowspan="1" colspan="1" valign="top" align="center">44.4 (12.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">40.4 (13.0)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> HAQ-DI (range, 0–3)</td>
<td rowspan="1" colspan="1" valign="top" align="center">1.6 (0.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">1.3 (0.7)</td>
<td rowspan="1" colspan="1" valign="top" align="center">1.6 (0.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">1.5 (0.7)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> mTSS</td>
<td rowspan="1" colspan="1" valign="top" align="center">15.5 (20.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">12.2 (17.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">20.7 (22.1)</td>
<td rowspan="1" colspan="1" valign="top" align="center">12.4 (18.6)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">CRRP, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">146 (28)</td>
<td rowspan="1" colspan="1" valign="top" align="center">25 (15)</td>
<td rowspan="1" colspan="1" valign="top" align="center">NA</td>
<td rowspan="1" colspan="1" valign="top" align="center">NA</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Insufficient responders, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">NA</td>
<td rowspan="1" colspan="1" valign="top" align="center">NA</td>
<td rowspan="1" colspan="1" valign="top" align="center">146 (85)</td>
<td rowspan="1" colspan="1" valign="top" align="center">364 (73)</td>
</tr>
<tr><td colspan="5" rowspan="1" valign="top" align="left">Prior therapies, n (%)</td></tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> Systemic glucocorticoids</td>
<td rowspan="1" colspan="1" valign="top" align="center">216 (41)</td>
<td rowspan="1" colspan="1" valign="top" align="center">79 (49)</td>
<td rowspan="1" colspan="1" valign="top" align="center">61 (36)</td>
<td rowspan="1" colspan="1" valign="top" align="center">225 (45)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left"> ≥1 DMARD</td>
<td rowspan="1" colspan="1" valign="top" align="center">88 (17)</td>
<td rowspan="1" colspan="1" valign="top" align="center">28 (17)</td>
<td rowspan="1" colspan="1" valign="top" align="center">34 (20)</td>
<td rowspan="1" colspan="1" valign="top" align="center">78 (16)</td>
</tr>
</tbody>
</table></div>
<div id="largeobj_idm140576998550624" class="largeobj-link align_right" style="display: none"><a target="object" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225797/table/T1/?report=objectonly">Open in a separate window</a></div>
<div class="tblwrap-foot">
<div id="tblfn1"><p id="__p17" class="p p-first-last">Values are mean (SD), unless otherwise indicated.</p></div>
<div id="tblfn2"><p id="__p18" class="p p-first-last">Insufficient
 response to methotrexate was defined as not achieving 
DAS28(CRP) &lt;3.2 at week 24/26 for OPTIMA or week 20/24 for 
PREMIER.</p></div>
<div id="tblfn3"><p id="__p19" class="p p-first-last">CRRP was defined as an increase in mTSS of &gt;1.5 from baseline to week 26 for OPTIMA or week 24 for PREMIER.</p></div>
<div id="tblfn4"><p id="__p20" class="p p-first-last">CDAI,
 Clinical Disease Activity Index; CRP, C-reactive protein; CRRP, 
clinically relevant radiographic progression; DAS28(CRP), 28-joint 
Disease Activity Score based on CRP; DMARD, disease-modifying 
antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability 
Index; mTSS, modified total Sharp score; NA, not available; 
OPTIMA, Optimal Protocol for Treatment Initiation with Methotrexate
 and Adalimumab; RA, rheumatoid arthritis; SDAI, Simplified Disease
 Activity Index; SJC66, swollen joint count based on 66 joints; TJC68, 
tender joint count based on 68 joints.</p></div>
</div>
</div>